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THE ARTICLE BY Giordano et al. in the current issue of Thy-roid (1) highlights many interesting issues concerning the
nature of apoptosis in the thyroid and the role it may play
in autoimmune thyroid disease. The authors examined the
expression of Fas antigen and ligand on thyroid cells from
patients with Graves’ and Hashimoto’s diseases and com-
pared this to normal thyroids. In addition, they evaluated
levels of Bcl-2, an apoptosis regulatory protein, in these cells.
They were also able to examine the expression of these mol-
ecules in lymphocytes infiltrating the thyroid in the autoim-
mune disorders. The results reinforce the hypothesis that
regulation of apoptosis in thyroid cells may alter the ex-
pression of autoimmune thyroid disease, a concept currently
advanced by several laboratories including my own (2–4).
However, the authors’ specific findings raise a number of
questions concerning the nature of apoptosis regulation and
the actual mechanisms involved in inducing cell death in au-
toimmune disease.
Giordano and colleagues found that there was differential
expression of Fas pathway molecules in Graves’ and
Hashimoto’s thyroid cells (see Fig. 1 for summary). While
both types of thyroid cells reportedly expressed Fas ligand,
there were marked increases in the expression of this pro-
tein in Hashimoto’s thyrocytes as compared with Graves’ or
normal cells. The expression of Fas antigen was also upreg-
ulated in Hashimoto’s thyrocytes. The authors also found
that concentrations of Bcl-2 were elevated in Graves’ cells
compared to control thyroids, and suppressed in Hashi-
moto’s cells. In contrast, they found that lymphocytes from
Graves’ disease patients have elevated levels of Bcl-2 and de-
creased expression of Fas ligand, and while Hashimoto’s
lymphocytes had decreased expression of Bcl-2. They inter-
pret these findings to suggest that there is a general proapop-
totic milieu for Hashimoto’s thyroid cells and an antiapop-
totic potential for Graves’ cells. This was contrasted with a
proapoptotic and noncytotoxic potential in the lymphocytes
infiltrating Graves’ disease thyroids and an antiapoptotic po-
tential in the Hashimoto’s gland lymphocytes. The authors
believe that these results argue that the apoptotic potential
of the thyroid cell is crucial to the manifestation of autoim-
mune disease, leading either to glandular destruction in thy-
roiditis or to growth in Graves’ disease.
While I am in general agreement with the authors’ hy-
pothesis that apoptosis is regulated in thyroid cells, the ac-
tual role that the Fas pathway proteins play in thyroid cell
apoptosis is not clear from this work. There is some support
for the concept that Fas-mediated apoptosis is regulated
through alterations in the levels of signaling and receptor
proteins (5,6). However, the changes in the levels of ex-
pressed Fas antigen and ligand and observed in these cells
may not be adequate to alter the induction of apoptosis (5).
The authors’ argument for regulation of the Fas pathway in
this manner is further weakened by the absence of any func-
tional data showing differences in signal transduction asso-
ciated with these changes in Fas receptor and ligand. The
most impressive difference the authors’ demonstrate be-
tween Graves and Hashimoto’s cells was in the expression
of Fas ligand. Levels of Fas ligand protein on Hashimoto’s
thyrocytes were three logs higher than background strain-
ing, and a full log greater than the levels the authors doc-
ument on lymphocytes from similar glands (Figure 4 in 
Giordano et al.’s article). This level of Fas expression in
Hashimoto’s thyroid cells is truly remarkable given that ac-
tivated lymphocytes are one of the cells with the highest ob-
Division of Allergy and Immunology, Center for Biological Nanotechnology, Department of Internal Medicine, University of Michigan
Medical School, Ann Arbor, Michigan.
Supported by RO1 A137141.
FIG. 1. Giordano et al’s proposed differences in apop-
totic molecules and potential for thyroid follicular cells
and intrathyroidal lymphocytes in Graves’ and
Hashimoto’s diseases.
served levels of Fas ligand expression (7), and would sug-
gest a unique activation of the Fas ligand transcription in
these cells. However, these data are controversial because
the expression of Fas ligand has not been consistently ob-
served in thyroid cells (2–4,8,9) and this level of expression
has not been previously observed in other cells (5).
The high level of Fas antigen expression on Hashimoto’s
thyrocytes also observed in this report may have functional
significance as it could overwhelm inhibitory molecules that
compete for caspace binding with Fas such as FAP, which
has been identified in the thyroid (8,9). Potential support for
this concept comes from a 1999 report from my laboratory
that showed papillary thyroid cancer cells express high lev-
els of Fas antigen and this expression appeared to relate to
increase susceptibility to Fas pathway activation (10). How-
ever, a majority of publications do not support alterations in
the levels of Fas antigen on thyroid cells in autoimmune dis-
eases (11,12). In particular, a recent article in Nature Medicine
by Stassi and coworkers (13), also from the University of
Palermo and occasional collaborators of Giordano, did not
show significant differences in the expression of Fas antigen
or ligand in Graves and Hashimoto’s thyrocytes. That report
and an earlier publication from my laboratory (14) both in-
dicate that the regulation of the Fas pathway in thyroid cells
involves inflammatory cytokines and that alterations in sig-
nal transduction occur without changes in the concentrations
of pathway components. Thus, while regulation of Fas me-
diated apoptosis may be important in the expression of au-
toimmune thyroid disease, the mechanisms regulating this
and the relative role this pathway plays in mediating disease
require further clarification.
The authors’ also hypothesize that Bcl-2 is important in
regulating apoptosis in thyroid cells, and this concept is bet-
ter supported by publications from other groups (9). In par-
ticular, work suggesting that Bcl-2 regulation is important in
the apoptotic potential of cells has come primarily from can-
cer cell lines where increased levels of Bcl-2 or decreased lev-
els of proapoptotic proteins, such as Bclx, has been associ-
ated with increased survival potential and resistance to
apoptosis (15,16). The Bcl-2 family of proteins is important
in regulating apoptosis triggered by several mechanisms in-
cluding oxidative stress, radiation damage, or abnormal cell
division (15,17). However, the role that Bcl-2 might play in
preventing apoptosis associated with autoimmune attack 
is not clear. This is especially true for signaling occurring
through membrane receptors, such as Fas, where Bcl-2 has
consistently been unable to block apoptosis (18,19). In addi-
tion, in pathways where Bcl-2 does block apoptosis it is the
ratio of proapoptotic to antiapoptotic proteins that deter-
mines the overall potential for apoptosis (15). Unfortunately,
the current article fails to provide levels of proapoptotic pro-
teins for comparison and presents no functional data sup-
porting a role for Bcl-2 in this particular setting. Thus, while
Bcl-2 may alter the apoptotic potential of thyroid cells, it
would not be expected to prevent apoptosis mediated by at-
tacking lymphocytes through either the tumor necrosis fac-
tor, Fas, or TRAIL receptors that are present on thyroid cells
(20).
The reasons behind the changes in apoptotic proteins ob-
served by Giordano et al. are also of interest. As suggested
above, one might presume that these changes are secondary
to inflammatory events in the thyroid. This would certainly
make sense when examining the alterations in the thyroid
cells, but does not fully explain why the lymphocyte popu-
lations would be so different. In that regard, it could be that
reported differences in the expression of cytokines or co-
stimulatory molecules by thyroid cells in Graves’ versus
Hashimoto’s diseases would yield different lymphocytes
populations (21,22). It is also possible that cytokines elabo-
rated as a result of the “thyrotoxic state” could alter either
thyroid follicular cells or lymphocytes (23). What seems less
likely is a genetic difference in the regulation of these path-
ways in patients with Graves’ or Hashimoto’s diseases. It is
still possible that genetic factors could be involved, but this
would probably also require environmental inputs to medi-
ate the specific and contrary status of the apoptotic machin-
ery on these two cell types.
In conclusion, while regulation of apoptosis is likely to be
important in the expression of autoimmune disease, the spe-
cific mechanisms of regulation in the thyroid remain un-
known. Activation of apoptosis can occur through a number
of pathways that are similar in function but entirely inde-
pendent in signal transduction. It is also likely that regula-
tion of apoptosis or the apoptotic potential of thyroid cells
may change over the course of autoimmune disease, allow-
ing for the initiation or perpetuation of thyroid damage. Be-
cause it is impossible to examine the human thyroid during
the evolution of the autoimmune process, it may be impor-
tant to evaluate mouse models of Graves’ and Hashimoto’s
disease to better clarify the role of proapoptotic and anti-
apoptotic forces that play a role in mediating the destruction
or growth of human thyroid cells. This remains an extremely
important area for clarification because it may allow for the
manipulation of apoptotic pathways, perhaps leading to
therapies that prevent thyroid dysfunction in patients with
antithyroid autoimmunity (24).
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